Arsenic trioxide inhibites transgenic tumor necrosis factor-α promoter activity in vascular smooth muscle cells and THP-1 monocytes in vitro

Abstract

Abstract: Aim This study was to evaluate the effect of arsenic trioxide (As2O3) on the transgenic TNF-α promoter activity in cultured vascular smooth muscle cells (VSMCs) and THP-1 monocytes. Methods Human TNF-α promoter was constructed by reporter gene system and was transiently transfected into VSMCs and THP-1 in vitro. The promoter activity was tested by luciferase activity with or without LPS and Ang II stimulation, before and after different dosage of As2O3 treatment. Results 1. TNF-α promoter effectively expressed in VSMCs and THP-1 compared with CMV promoter (58.3% and 80.9%, respectively). Both LPS and Ang II significantly up-regulated TNF-α promoter activity (P<0.05). 2. As2O3 significantly inhibited, both intact and LPS/Ang II stimulated promoter activity, in a dose dependent manner (P<0.05), and in both cell type. Conclusion These results manifested that, the inhibition effect of As2O3 on the activity of human TNF-α promoter indicated its potential inhibition on pro-inflammatory cytokine genes expression at transcriptional level and its potential anti-inflammatory property in the cardiovascular system.

Key words: Arsenic trioxide, Arsenic trioxide, TNF-α promoter, TNF-α promoter, Inflammation, Inflammation, Smooth muscle cells, Smooth muscle cells, Vascular, Vascular, Monocytes, Monocytes

CLC Number:

R965

Supporting:

Zhuo-Qi Zhang^*, Xi-Chuan Cao, Yong-Lin Huang. Arsenic trioxide inhibites transgenic tumor necrosis factor-α promoter activity in vascular smooth muscle cells and THP-1 monocytes in vitro[J]. .

References

[1] Ross R. Atherosclerosis—an inflammatory disease [J]. N Engl J Med, 1999, 340 (2): 115–126.
[2] Donners MM, Daemen MJ, Cleutjens KB, et al. Inflammation and restenosis: implications for therapy [J]. Ann Med, 2003, 35 (7): 523–531.
[3] Clausell N, de Lima VC, Molossi S, et al. Expression of tumour necrosis factor alpha and accumulation of fibronectin in coronary artery restenotic lesions retrieved by atherectomy [J]. Br Heart J, 1995, 73 (6): 534–539.
[4] Adkins JR, Castresana MR, Wang Z, et al. Rapamycin inhibits release of tumor necrosis factor-alpha from human vascular smooth muscle cells [J]. Am Surg, 2004, 70 (5): 384–387.
[5] Peppel K, Zhang L, Orman ES, et al. Activation of vascular smooth muscle cells by TNF and PDGF: overlapping and complementary signal transduction mechanisms [J]. Cardiovasc Res, 2005, 65 (3): 674–682.
[6] Zhu J, Chen Z, Lallemand-Breitenbach V, et al. How acute promyelocytic leukaemia revived arsenic [J]. Nat Rev Cancer, 2002, 2 (9): 705–713.
[7] Luan TZ, Mei Y, Xu DX, et al. Effect of arsenic trioxide on rabbit vascular smooth muscle cells after balloon angioplasty [J]. Natl Med J China, 2003, 83 (10): 859– 861.
[8] Zhao Z, Huang C, Wang J, et al. Effect of arsenic trioxide on inhibition of restenosis after rabbit vascular injury and its mechanism [J]. Chin Med J (Engl), 2002, 115 (11): 1608–1614.
[9] Dartsch PC, Voisard R, Bauriedel G, et al. Growth characteristics and cytoskeletal organization of cultured smooth muscle cells from human primary stenosing and restenosing lesions [J]. Arteriosclerosis, 1990, 10 (1): 62– 75.
[10] Staniforth V, Wang SY, Shyur LF, et al. Shikonins, phytocompounds from Lithospermum erythrorhizon, inhibit the transcriptional activation of human tumor necrosis factor alpha promoter in vivo [J]. J Biol Chem, 2004, 279 (7): 5877–5885.
[11] Zhou Z, Lauer MA, Wang K, et al. Effect of anti-tumor necrosis factor-alpha polyclonal antibody on restenosis after balloon angioplasty in a rabbit atherosclerotic model [J]. Atherosclerosis, 2002, 161 (1): 153–159.
[12] Javed Q, Swanson N, Vohra H, et al. Tumor necrosis factor-alpha antibody eluting stents reduce vascular smooth muscle cell proliferation in saphenous vein organ culture [J]. Exp Mol Pathol, 2002, 73 (2): 104–111.
[13] Tang X, Fenton MJ, Amar S. Identification and functional characterization of a novel binding site on TNF-alpha promoter [J]. Proc Natl Acad Sci USA, 2003, 100 (7): 4096–4101.
[14] Subbaramaiah K, Bulic P, Lin Y, Dannenberg AJ, et al. Development and use of a gene promoter-based screen to identify novel inhibitors of cyclooxygenase-2 transcription [J]. J Biomol Screen, 2001, 6 (2): 101–110.
[15] Yang X, Coriolan D, Murthy V, et al. Proinflammatory phenotype of vascular smooth muscle cells: role of efficient Toll-like receptor 4 signaling [J]. Am J Physiol Heart Circ Physiol, 2005, 289 (3): H1069–1076.
[16] Browatzki M, Larsen D, Pfeiffer CA, et al. Angiotensin II stimulates matrix metalloproteinase secretion in human vascular smooth muscle cells via nuclear factorkappaB and activator protein 1 in a redox-sensitive manner [J]. J Vasc Res, 2005, 42 (5): 415–423.
[17] Oliveira MV, Badia E, Carbonneau MA, et al. Potential anti-atherogenic cell action of the naturally occurring 4- O-methyl derivative of gallic acid on Ang II-treated macrophages [J]. FEBS Lett, 2004, 577 (1-2): 239–244.
[18] Sato H, Watanabe A, Tanaka T, et al. Regulation of the human tumor necrosis factor-alpha promoter by angiotensin II and lipopolysaccharide in cardiac fibroblasts: different cis-acting promoter sequences and transcriptional factors [J]. J Mol Cell Cardiol, 2003, 35 (10): 1197–1205.
[19] Singh U, Tabibian J, Venugopal SK, et al. Development of an in vitro screening assay to test the antiinflammatory properties of dietary supplements and pharmacologic agents [J]. Clin Chem, 2005, 51 (12): 2252–2256.